PSMA PET-Targeted Biopsy Detects Prostate Cancers Missed by Ultrasound: Study
A recent study demonstrates that Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy (PSMA PET-TB) delivers a remarkable 97.06% diagnostic yield, successfully identifying 90.7% of prostate cancers missed by traditional ultrasound, as published in the African Journal of Urology in October 2025.
While systematic transrectal ultrasound-guided (TRUS) biopsy is the clinical standard, its 35% false-negative rate creates a significant diagnostic gap for high-suspicion patients. To address this, Dr. Abhishek Choube and colleagues from the All India Institute of Medical Sciences, Bhopal, investigated if 68 Ga-PSMA PET-targeted biopsy could serve as a superior alternative for diagnosing these challenging cases.
Therefore, over 23 months, the prospective study at a North Indian tertiary center evaluated 129 men with suspected malignancy, specifically focusing on 43 patients with PSMA-avid lesions following an initial negative 12-core biopsy. Diagnostic performance was analyzed using SUVmax thresholds and ROC curves, while strictly excluding patients with non-avid lesions or active infections.
Key Clinical Findings of the Study Includes:
High Diagnostic Accuracy: The study reports that PSMA PET-targeted biopsy achieved an overall diagnostic accuracy of 83.72%, successfully confirming adenocarcinoma in 39 of 43 patients previously deemed negative by standard methods.
Detection of Hidden Lesions: The targeted technique identified 94.9% of cancers located in the anterior zone of the prostate, a region where traditional ultrasound-guided biopsies frequently fail to detect malignant tissue.
Validated Thresholds: By applying an SUVmax cut-off of 6.95, the modality demonstrated a strong sensitivity of 84.62% and a specificity of 75% for detecting clinically suspicious malignancy.
Prognostic Value: There was a statistically significant correlation (p < 0.00001) between the intensity of tracer uptake and the pathological Gleason grade group, highlighting the tool's ability to reflect disease severity.
The results suggest that PSMA PET-targeted biopsy is a highly reliable second-line diagnostic tool that can effectively bridge the gap left by conventional imaging, particularly as it detected over 90% of cancers missed by the initial gold-standard biopsy.
Thus, the study concludes clinicians may find that proceeding directly to this targeted approach for high-risk, TRUS-negative patients is a more efficient diagnostic pathway than repeating systematic biopsies or relying solely on magnetic resonance imaging fusion, especially in environments where resources are limited.
While the study's findings are limited by its single-center design and the unavailability of multiparametric magnetic resonance imaging for approximately 37% of the cohort, further multicentric research involving larger and more diverse patient populations will be valuable to confirm its clinical efficacy across broader demographics.
Reference
Choube, A., Phonde, A., & Balaji, S. (2025). Evaluation of the diagnostic yield of PSMA PET-guided targeted biopsy over TRUS-guided biopsy in clinically suspicious prostate cancer: single-center experience from Northern India. African Journal of Urology, 31:60.
